オハイオにおけるリンパ腫の臨床試験
オハイオ内の拠点で、リンパ腫に関する29件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- University Hospitals Seidman Cancer Center, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06343311A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第2相
1 Month – 17 Years · 全性別 · 2026/09/30更新 · NCT04570423A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- Cleveland Clinic, Cleveland
- The Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07015242Epco, Zanu, Ritux for R/R FL or MZL
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06563596Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1相
24 Months – 18 Years · 全性別 · 2026/09/25更新 · NCT06441331Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT04301076A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Cincinnati, Cincinnati
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
- 他1件
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/17更新 · NCT07221500Collection of Tissue Samples for Cancer Research
- Ohio State University, Columbus
被験者募集中観察研究
2 Months · 全性別 · 2026/09/16更新 · NCT00900198CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1/2相
12 Months – 21 Years · 全性別 · 2026/09/11更新 · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Cleveland
被験者募集中第3相
18歳〜18歳 · 全性別 · 2026/09/08更新 · NCT07509151Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Cincinnati (UC) Physicians Company, LLC, Cincinnati
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/08/20更新 · NCT06678659A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Cincinnatti Medical Center, Cincinnatti
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT06528301Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Oncology Hematology Care Clinical Trials, Cincinnati
- University of Cincinnati, Cincinnati
- Cleveland Clinical Taussig Cancer Center, Cleveland
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/04更新 · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- The Ohio State University Wexner Medical Center James Cancer, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/13更新 · NCT04792489A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
- University Hospitals Cleveland Medical Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/08更新 · NCT07465835A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/02更新 · NCT05131022A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/17更新 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/18更新 · NCT01790152Trial to Evaluate the Safety & Tolerability of JBZ-001 in Pts With Advanced Solid and Hematological Malignancies
- The Ohio State University, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/04/24更新 · NCT06801002CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Cleveland Clinic, Cleveland
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/15更新 · NCT07356245The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2025/11/10更新 · NCT06916767HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
被験者募集中観察研究
12歳〜80歳 · 全性別 · 2025/08/28更新 · NCT07145411ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。